drugset / Trial / NCT02516774
A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and radiotherapy in order to counteract tumor resistance to therapy.
Timeline
- Start
- 2014-12
- Primary completion
- 2015-12
- Completion
- 2015-12
Outcome
Outcome not reported
Stopped (Enrollment): “No patients enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | — | Subcutaneous |